We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$140M
AUM Growth
-$45.1M
Cap. Flow
-$17.3M
Cap. Flow %
-12.34%
Top 10 Hldgs %
93.49%
Holding
21
New
–
Increased
–
Reduced
2
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$16.7M
2
OBSV
ObsEva SA Ordinary Shares
OBSV
+$596K
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$26.4K
4
ZSAN
Zosano Pharma Corporation
ZSAN
+$2

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$55.1M 39.31%
6,068,125
– –
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.69B
$19.7M 14.07%
1,025,000
– –
GLUE icon
3
Monte Rosa Therapeutics
GLUE
$1.4B
$14.2M 10.16%
1,472,331
– –
BMEA icon
4
Biomea Fusion
BMEA
$84.6M
$9.57M 6.83%
798,757
– –
ACRS icon
5
Aclaris Therapeutics
ACRS
$726M
$8.86M 6.32%
634,455
– –
NUVB icon
6
Nuvation Bio
NUVB
$2.2B
$8.23M 5.87%
2,541,009
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$5.58M 3.98%
1,332,485
– –
ELEV
8
DELISTED
Elevation Oncology
ELEV
$3.97M 2.83%
2,834,910
– –
TRML
9
DELISTED
Tourmaline Bio
TRML
$3.08M 2.2%
68,292
– –
PSTX
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.69M 1.92%
1,043,267
– –
OKUR
11
OnKure Therapeutics
OKUR
$154M
$2.35M 1.68%
88,608
– –
SPRB
12
Spruce Biosciences
SPRB
$118M
$2.1M 1.5%
16,073
– –
VIRX
13
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.12M 0.8%
288,571
– –
MRKR icon
14
Marker Therapeutics
MRKR
$18.8M
$1.04M 0.74%
314,286
– –
TECX
15
Tectonic Therapeutic
TECX
$529M
$929K 0.66%
84,148
– –
SYRE icon
16
Spyre Therapeutics
SYRE
$8.54B
$854K 0.61%
67,646
– –
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$694K 0.5%
387,653
– –
ZSAN
18
DELISTED
Zosano Pharma Corporation
ZSAN
$24K 0.02%
77,663
-1
-0% -$2
NBRV
19
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$16K 0.01%
3,600
-4,041
-53% -$26.4K
HRMY icon
20
Harmony Biosciences
HRMY
$2.04B
– –
-342,815
Closed -$16.7M
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-394,838
Closed -$596K

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Aisling Capital Management held 21 positions worth $140M, down 24% from $185M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Aisling Capital Management withdrew a net $17.3M in Q2 2022, closing 2 positions and reducing 2 holdings. Its most notable exit was Harmony Biosciences, an estimated $16.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's biggest Q2 2022 reduction was Nabriva Therapeutics plc Ordinary Shares Ireland, cutting an estimated $26.4K.
  • Aisling Capital Management fully exited Harmony Biosciences in Q2 2022, selling an estimated $16.7M.
  • Aisling Capital Management's ten largest holdings make up 93% of its $140M portfolio in Q2 2022.
  • Aisling Capital Management opened 0 new positions and closed 2 in Q2 2022.
  • Aisling Capital Management's portfolio value fell 24% quarter-over-quarter to $140M.

Based on Aisling Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.